Novo Nordisk A/S $NVO is Oak Family Advisors LLC's 5th Largest Position

Key Points

• Oak Family Advisors LLC increased its stake in Novo Nordisk A/S by 61.8%, making it the firm's 5th largest position, with holdings valued at approximately $9.76 million.
• Recent analyst ratings have varied, with Zacks Research downgrading the stock to "strong sell," while Rothschild Redb upgraded it to "strong buy," reflecting a mixed outlook among financial experts.
• Novo Nordisk reported $0.97 earnings per share for the last quarter, exceeding expectations, but also announced a semi-annual dividend of $0.4119 per share.

Oak Family Advisors LLC raised its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 61.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 141,380 shares of the company's stock after buying an additional 54,027 shares during the quarter. Novo Nordisk A/S makes up approximately 3.1% of Oak Family Advisors LLC's portfolio, making the stock its 5th biggest position. Oak Family Advisors LLC's holdings in Novo Nordisk A/S were worth $9,758,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bennett Selby Investments LP lifted its stake in Novo Nordisk A/S by 14.2% in the second quarter. Bennett Selby Investments LP now owns 51,231 shares of the company's stock valued at $3,536,000 after buying an additional 6,355 shares during the last quarter. Janney Capital Management LLC acquired a new stake in Novo Nordisk A/S during the 2nd quarter worth approximately $9,876,000. Janney Montgomery Scott LLC lifted its position in Novo Nordisk A/S by 1.1% during the 2nd quarter. Janney Montgomery Scott LLC now owns 156,117 shares of the company's stock worth $10,775,000 after acquiring an additional 1,699 shares during the period. Venture Visionary Partners LLC lifted its position in Novo Nordisk A/S by 31.1% during the 2nd quarter. Venture Visionary Partners LLC now owns 80,609 shares of the company's stock worth $5,564,000 after acquiring an additional 19,110 shares during the period. Finally, Smith Chas P & Associates PA Cpas lifted its position in Novo Nordisk A/S by 143.6% during the 2nd quarter. Smith Chas P & Associates PA Cpas now owns 197,466 shares of the company's stock worth $13,629,000 after acquiring an additional 116,413 shares during the period. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of recent research reports. Zacks Research cut Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research report on Wednesday, August 20th. Rothschild Redb raised Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 16th. UBS Group cut Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a report on Tuesday, August 5th. Berenberg Bank raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Wednesday, September 17th. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of "Hold" and a consensus target price of $75.33.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $55.52 on Tuesday. The stock has a fifty day moving average price of $55.84 and a 200 day moving average price of $64.23. The stock has a market cap of $247.90 billion, a PE ratio of 15.25, a P/E/G ratio of 2.11 and a beta of 0.66. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $120.56. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to analysts' expectations of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Sell-side analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were issued a dividend of $0.4119 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S's payout ratio is currently 22.53%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.